000 03384nam a22004215i 4500
999 _c11625
_d11625
001 11625
003 DE-He213
005 20210720040355.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 180831s2018 gw | s |||| 0|eng d
020 _a9783319933399
024 7 _a10.1007/978-3-319-93339-9
_2doi
040 _bspa
_dES-VaUE
050 4 _aRC280
_b.G46 2018 EB
245 1 0 _aGenitourinary Cancers
_cedited by Siamak Daneshmand, Kevin G. Chan.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2018.
300 _aVI, 308 p. 39 illus., 38 illus. in color.
_bonline resource
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 1 _aCancer Treatment and Research,
_x0927-3042 ;
_v175
490 _aMedicine (Springer-11650)
505 0 _aNew Imaging Techniques in Prostate Cancer -- Targeted ablative therapies for prostate cancer -- Prostate cancer markers -- Prognostic value of CTC’s in urologic cancers -- Management of Small Renal Masses -- Advances in the Treatment of Metastatic Renal Cell Carcinoma.-Imaging in urologic cancers -- Molecular prognostication in Bladder cancer -- Early cystectomy for high risk non-muscle invasive disease -- Care-coordination pathway after radical cystectomy -- Current role of checkpoint inhibitors in urologic cancers -- ) The Cancer Genome Atlas Project -- Prognostic models in germ cell tumors -- Modern management of testicular cancer.
520 _aThis book addresses the most pressing current questions in the management of urologic malignancies. Placing the rapid advances in imaging and molecular markers into a clinical context, it explains their effects on prognosis and treatment planning. Similarly, it carefully examines advances in immunotherapy, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, it reviews the impacts of care coordination pathways and enhanced recovery after surgery protocols. Futher, the book includes an enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The final two chapters are devoted to testicular cancer: the first discusses recent advances in prognostication, while the second elucidates contemporary medical and surgical management.
653 0 _aOncology  .
653 0 _aUrology.
700 1 _aDaneshmand, Siamak.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aChan, Kevin G.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106996
776 0 8 _iPrinted edition:
_z9783319933382
776 0 8 _iPrinted edition:
_z9783319933405
830 0 _aCancer Treatment and Research,
_x0927-3042 ;
_v175
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-93339-9
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0